N-hydroxy-4-((4-(trifluoromethoxy)benzyl)sulfonamido)benzamide

N-hydroxy-4-((4-(trifluoromethoxy)benzyl)sulfonamido)benzamide, also known as Compound 7d, is a potent and selective small molecule inhibitor of histone deacetylase 6 (HDAC6). Developed by researchers at the University of Sassari, this compound belongs to a series of hydroxamate-based sulfonamides designed to target the unique catalytic site of the HDAC6 isoform. Unlike pan-HDAC inhibitors, Compound 7d demonstrates significant selectivity for HDAC6 over Class I and Class IIa HDACs. HDAC6 is primarily a cytoplasmic enzyme that regulates the acetylation status of non-histone proteins, most notably alpha-tubulin, Hsp90, and cortactin. By inhibiting HDAC6, Compound 7d increases tubulin acetylation, which can disrupt microtubule-dependent processes such as cell motility and protein degradation. This mechanism makes it a valuable tool for investigating potential treatments for oncology (e.g., multiple myeloma), neurodegenerative disorders (e.g., Charcot-Marie-Tooth disease and Alzheimer's), and inflammatory conditions. It is currently in the preclinical discovery stage.

Other names

N-hydroxy-4-[[[4-(trifluoromethoxy)phenyl]methyl]sulfamoyl]benzamideN-hydroxy-4-(N-(4-(trifluoromethoxy)benzyl)sulfamoyl)benzamide